User profiles for Alyssa Pereslete
 | Alyssa M PeresleteDana Farber Cancer Institute, Herbert Wertheim College of Medicine at Florida International Verified email at dfci.harvard.edu Cited by 55 |
Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases
…, T Li, AED Van Swearingen, Y Wang, A Pereslete… - Clinical Cancer …, 2023 - AACR
Purpose: Brain metastases can occur in up to 50% of patients with metastatic HER2-positive
breast cancer. Because patients with active brain metastases were excluded from previous …
breast cancer. Because patients with active brain metastases were excluded from previous …
[HTML][HTML] Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I …
The landscape of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistance is still being
elucidated and the optimal subsequent therapy to overcome resistance remains uncertain. …
elucidated and the optimal subsequent therapy to overcome resistance remains uncertain. …
Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients …
Even though multiple resistance mechanisms and pathways for cyclin-dependent kinase 4/6
inhibitors (CDK4/6i) have been discovered, the complete landscape of resistance is still …
inhibitors (CDK4/6i) have been discovered, the complete landscape of resistance is still …
Authorship diversity in global evidence synthesis in genitourinary oncology: A 1998-2022 analysis of cochrane reviews.
e23006 Background: Women and individuals from low- and lower-middle-income countries (LMICs)
are under-represented in oncology literature, particularly in high-impact publications…
are under-represented in oncology literature, particularly in high-impact publications…
Abstract PD7-03: translational breast cancer research consortium trial 022: neratinib and trastuzumab-emtansine for HER2+ breast cancer brain metastases (BCBM)
PURPOSE: Treatment options for patients (pts) with HER2+ BCBM remain limited. We
previously reported that neratinib monotherapy is associated with a volumetric central nervous …
previously reported that neratinib monotherapy is associated with a volumetric central nervous …
Abstract PD4-05: Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases (BCBM)
…, AED Van Swearingen, Y Wang, AM Pereslete… - Cancer Research, 2022 - AACR
Purpose: Up to half of patients (pts) with HER2+ metastatic breast cancer (MBC) will
develop BCBM. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) with …
develop BCBM. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) with …
Abstract P4-01-06: Genomic and transcriptomic analysis reveals known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response …
Background: Multiple studies in HR+/HER2- MBC have identified a variety of genomic
resistance mechanisms to CDK4/6 inhibitors, but the complete landscape of resistance …
resistance mechanisms to CDK4/6 inhibitors, but the complete landscape of resistance …
Ethnic disparities in biomarker testing and targeted therapy use in metastatic lung adenocarcinoma: A 2014-2021 analysis.
e21216 Background: Racial and ethnic disparities have been demonstrated to be widespread
in lung cancer, including in the US. Despite insurance coverage for standard biomarker …
in lung cancer, including in the US. Despite insurance coverage for standard biomarker …
Abstract PS11-06: Analysis of HER2 expression changes from breast primary to brain metastases including HER2 Low and impact on overall survival
A Pereslete, M Hughes, A Patterson, J Files, K Nguyen… - Cancer Research, 2024 - AACR
Background: Previous studies have shown that breast cancer receptor subtype switching
between matched primary and metastatic brain metastases (BrM) is common. HER2 …
between matched primary and metastatic brain metastases (BrM) is common. HER2 …
Abstract PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
…, M Hughes, R Kusmick, L Alder, A Pereslete… - Cancer Research, 2024 - AACR
Background: trastuzumab deruxtecan (T-DXd) is a standard treatment for patients (pts) with
HER2-positive (HER2+) and HER2-low metastatic breast cancer (MBC). HER2-low …
HER2-positive (HER2+) and HER2-low metastatic breast cancer (MBC). HER2-low …
